The investigation focuses on whether the company issued misleading and/or false statements and/or failed to disclose information pertinent to investors. On August 11, 2020 The FDA released briefing materials for the August 13, 2020, meeting of the Oncologic Drugs Advisory Committee. The meeting was to discuss the marketing application of Mesoblast for Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. According to the FDA briefing documents, it was “unclear” if these study results are “relevant” to the proposed indication. On August 11, shares of Mesoblast fell by nearly 35% based on this news.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
8240 Beverly Blvd., Suite 9
Los Angeles, CA 90048